As researchers work to improve drug properties through drug design and molecular modeling, the line between drug delivery and drug substance will become more and more elusive in the near future, as shown in the analysis in this report. Consequently, in the next decade, drug delivery technologies will be a focal point of competition within the pharmaceutical industry and the needle-free drug delivery market will continue to grow rapidly.
This Kalorama Information report, Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccines and Biologics, takes a look at this aspect of the pharmaceutical marketplace, with figures and forecasts for pharmaceutical companies and the companies that supply technology to them. The report discusses how the success of specific drugs will be tied to innovative delivery techniques, which will enable the targeting that will exploit the clinical properties of a new generation of drugs.
The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to significant improvements in drug delivery. This report looks at that trend and provides current and forecasted revenues for the injectable drug delivery market, segmented into two main categories:
- Needle-Free Products Market (Including Drug and Technology)
- Needle-Free Products Market (Technology Only)
This breakout makes the report relevant to business plans of either device technology companies or pharmaceutical concerns. In addition, the following key information for business planners is included in the report:
- Trends in the Vaccine Market
- Market Size and Forecast for Needle-Free Vaccine Technology
- Trends in Biopharmaceuticals
- Leading Pharmaceutical Product Sold With Needle-Free Technologies
- Products in Development
- Detailed Profiles of Key Companies in Needle-Free Technologies
- Current Market Size and Forecasts to 2016
- Needle-Free Cost Savings, Autojets, Health Care Reform, and Other Trends and Developments
Companies Profiled in the report include:
- Alkermes, Inc.
- ALZA Corp.
- Antares Pharma, Inc.
- Bioject Medical Technologies, Inc.
- CyDex, Inc.
- MGI Pharma, Inc
- Nektar Therapeutics
- Pacira Pharmaceuticals, Inc.
- SurModics, Inc
- Zogenix Corporation
- AP Pharma
- Baxter BioPharma Solutions
- QLT USA, Inc
- Ypsomed Holding AG
The findings in this report are based on both primary and secondary research. Kalorama conducted comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. New technologies, market developments, and research and development trends and expenditures were identified through patent and database searches, as well as via interviews with key personnel. Person-to-person, email and telephone interviews were the primary method of gathering information.
All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
For Kalorama’s take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information’s Key Point Blog at http://kaloramakeypoint.blogspot.com/